Mylan (MYL) Miss Overshadowed by Mediocre Deal - Guggenheim

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SPY
8. SWKS
9. XYZ
10. FISV

Go back to Mylan (MYL) Miss Overshadowed by Mediocre Deal - Guggenheim

Mylan Full Year Adjusted Diluted EPS Up 21% to $4.30

February 10, 2016 4:11 PM EST

HERTFORDSHIRE, England and PITTSBURGH, Feb. 10, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and year ended December 31, 2015.

Financial Highlights

Full year adjusted total revenues of $9.45 billion, up 28% on a constant currency basis versus the prior year; GAAP total revenues of $9.43 billion. Excluding the impact of the acquisition of Abbott Laboratories' non-U.S. developed markets specialty and branded generics business (the "EPD Business"), full year adjusted total revenues increased 9% on a constant currency basis. Generics... More